PURPOSE: The purpose of this study is to report the first case, to our knowledge, of @entity548 occurring 1 hour after @entity9498 premedication in a @entity1 with previously undiagnosed @entity2479 and @entity323 . METHODS: This is an interventional case report. The @entity1 underwent Snellen vision acuity measurement, anterior and posterior segment biomicroscopy, and indirect ophthalmoscopy. Optical coherence tomography, @entity941 angiography, and @entity3194 angiography were also performed as needed. Recombinant tissue plasminogen activator 100  g/0.1 mL and 0.3 mL pure SF6 gas were injected in the vitreous on presentation. Four days later, the @entity1 received 1.25 mg/0.1 mL of intravitreal bevacizumab. RESULTS: One day after recombinant tissue plasminogen activator and gas injection, visual acuity rose to 20/60-2. A week later, visual acuity was unchanged, and the subretinal @entity548 displaced from the foveola. Optical coherence tomography showed a marked regression of submacular thickening. CONCLUSION: Despite strict time correlation, the submacular @entity548 cannot be unequivocally attributed to @entity9498 assumption because many other risk factors are to be considered: the Valsalva maneuver above all. Nonetheless, a suspicion should be raised, at least as a cofactor, given the drug mechanism of action and the report of @entity455 bleeding in the literature, including cerebral @entity600 and @entity1415 . Caution should be exercised in the prescription of phosphodiesterase type 5 inhibitors to @entity1 with known @entity455 including retinal and @entity3193 : @entity2479 , classic and occult neovascularization of any origin, and also, possibly, @entity2695 .

Intracoital @entity548 after XXXX (cialis) premedication: a case report.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular abnormalities'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'intracoital subfoveal hemorrhage'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal angiomatous proliferation'] @entity2695 :: ('MESH:D006391', 'Disease') :: ['hemangioma'] @entity1415 :: ('MESH:D004844', 'Disease') :: ['epistaxis'] @entity9498 :: ('MESH:C429886', 'Chemical') :: ['tadalafil'] @entity3194 :: ('MESH:D007208', 'Chemical') :: ['indocyanine green'] @entity600 :: ('MESH:D000014', 'Disease') :: ['arterovenous malformation'] @entity3193 :: ('MESH:D015862', 'Disease') :: ['choroidal abnormalities'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']
@entity9498 :: (MESH:C429886,Chemical) :: ['tadalafil']
